Table 1.
Patient demographic, clinical, and tumor characteristics
| Total N = 45 | Survivor N = 34 | Nonsurvivor N = 11 | P‑value | |
|---|---|---|---|---|
| Age, years | 66.0 (58.0–74.0) | 61.5 (57.0–72.0) | 70.0 (67.0–80.0) | 0.0207 |
| Sex | 0.1318 | |||
| Male | 31 (68.9) | 21 (61.8) | 10 (90.9) | |
| Female | 14 (31.1) | 13 (38.2) | 1 (9.1) | |
| History of smoking | 11 (24.4) | 8 (23.5) | 3 (27.3) | 1.0000 |
| Comorbidity | ||||
| Hypertension | 15 (33.3) | 8 (23.5) | 7 (63.6) | 0.0256 |
| Coronary artery disease | 7 (15.6) | 4 (11.8) | 3 (27.3) | 0.3368 |
| Diabetes | 6 (13.3) | 3 (8.8) | 3 (27.3) | 0.1459 |
| Other | 19 (42.2) | 13 (38.2) | 6 (54.5) | 0.4851 |
| Early symptoms of COVID‐19 | ||||
| Fever | 33 (73.3) | 25 (73.5) | 8 (72.7) | 1.0000 |
| Cough | 24 (53.3) | 18 (52.9) | 6 (54.5) | 1.0000 |
| Chest tightness | 8 (17.8) | 6 (17.6) | 2 (18.2) | 1.0000 |
| Shortness of breath | 7 (15.6) | 6 (17.6) | 1 (9.1) | 0.6628 |
| Fatigue | 6 (13.3) | 5 (14.7) | 1 (9.1) | 1.0000 |
| Sputum production | 5 (11.1) | 2 (5.9) | 3 (27.3) | 0.0853 |
| COVID‐19 disease severity | <0.0001 | |||
| Mild | 4 (8.9) | 4 (11.8) | 0 (0.0) | |
| Moderate | 18 (40.0) | 18 (52.9) | 0 (0.0) | |
| Severe | 12 (26.7) | 12 (35.3) | 0 (0.0) | |
| Critical | 11 (24.4) | 0 (0.0) | 11 (100.0) | |
| Time from COVID‐19 onset to hospital admission, days | 10.0 (6.5–14.5) | 10.0 (7.0–18.0) | 8.0 (2.0–12.0) | 0.0724 |
| Type of lung cancer | 0.0468 | |||
| Lung adenocarcinoma | 10 (22.2) | 6 (17.6) | 4 (36.4) | |
| Lung squamous cell cancer | 5 (11.1) | 4 (11.8) | 1 (9.1) | |
| Small cell lung cancer | 2 (4.4) | 0 (0) | 2 (18.2) | |
| No information | 28 (62.2) | 24 (70.6) | 4 (36.4) | |
| Prior thoracic surgery | 19(42.2) | 15(44.1) | 4(36.4) | 0.7363 |
| Cancer status | 0.4578 | |||
| Remission | 14 (31.1) | 12 (35.3) | 2 (18.2) | |
| Present | 31 (68.9) | 22 (64.7) | 9 (81.8) | |
| Time from lung cancer to COVID‐19, years † | 1.0 (0.0–3.0) | 1.0 (0.0–3.0) | 1.0 (1.0–1.0) | 0.9126 |
| Cancer treatment within four weeks of COVID‐19 diagnosis | ||||
| Lung resection surgery | 3 (6.7) | 2 (5.9) | 1 (9.1) | 1.000 |
| Chemotherapy | 4 (8.9) | 2 (5.9) | 2 (18.2) | 0.2470 |
| Treatment with immune checkpoint inhibitors | 4 (8.9) | 3 (8.8) | 1 (9.1) | 1.0000 |
Data are presented as the median (interquartile), or number (%), where appropriate.
†
Times from the diagnosis of lung cancer to the diagnosis of COVID‐19.
COVID‐19, coronavirus disease 2019.